NeuroOne Submits 510(k) Application To FDA For OneRF Ablation System
Portfolio Pulse from Benzinga Newsdesk
NeuroOne has submitted a 510(k) application to the FDA for its OneRF Ablation System, a device designed to treat epilepsy and other neurological disorders. The approval could expand the company's product offerings and market reach.
June 12, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroOne's submission of a 510(k) application to the FDA for its OneRF Ablation System could potentially expand the company's product offerings and market reach.
The submission of the 510(k) application to the FDA is a crucial step for NeuroOne in getting approval for its OneRF Ablation System. If approved, this could lead to an expansion of the company's product offerings and market reach, potentially increasing its revenue and positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100